Full Spectrum Extract
Full Spectrum Extraction & Delivery
Why the extraction method and delivery format are as pharmacologically significant as the compound itself, and the mechanistic rationale behind Evōke's formulation decisions.
Full Spectrum vs Isolated Compounds
Most clinical psilocybin research uses synthesised or isolated psilocybin. Most traditional and contemporary microdosing practice uses whole or minimally processed material. The pharmacological difference between these approaches is significant, and underexamined in the published literature.
The psilocybin fruiting body is a complex biochemical system. Beyond psilocybin, it contains baeocystin (a 4-phosphoryloxy-N-methyltryptamine), norbaeocystin, aeruginascin, and a range of beta-glucans, polysaccharides, and other constituents. Isolated psilocybin strips all of these. Full spectrum extraction preserves the complete alkaloid profile alongside the supporting matrix.
"The pharmacological fingerprint of full spectrum psilocybin extract is not the same as the fingerprint of isolated psilocybin, in the same way that whole-plant cannabis and isolated THC are pharmacologically distinct preparations."
The cannabis analogy is instructive. The well-documented entourage effect in cannabis, where cannabinoids, terpenes, and flavonoids interact to produce effects distinct from isolated THC, provides the conceptual framework. Whether a comparable interaction profile exists across psilocybin's alkaloid range is not yet established, but the mechanistic precedent is clear.
Why Format Determines Pharmacokinetics
First-pass hepatic metabolism
Oral psilocybin is subject to significant first-pass metabolism in the liver, converting psilocybin to psilocin before systemic circulation. The rate and completeness of this conversion varies with delivery format, fasting state, individual metabolic variation, and the composition of the preparation. A formulation that supports consistent conversion produces more consistent outcomes.
Honey as a delivery matrix
Honey's hygroscopic properties and pH range (3.4-6.1) create a stable, acidic matrix that protects alkaloid integrity during storage and may support consistent dissolution in the GI environment. The antimicrobial properties of honey provide natural preservation without the additives required in other formulation approaches. These are formulation decisions with pharmacological rationale, not aesthetic choices.
Dose consistency as a clinical value
Inconsistent dosing is the primary variable that undermines meaningful outcomes in self-directed microdosing practice. A formulation approach that prioritises dose consistency, through precise extraction, standardised delivery format, and quality-controlled preparation, is not an incremental improvement. It is the difference between a precision practice and an approximation.
The Amanita challenge
Amanita muscaria's bioavailability problem, inconsistent ibotenic acid to muscimol conversion and variable oral absorption, is the harder version of the same challenge. The formulation work required to solve it is more complex, which is why Amanita formulations are further behind in the development cycle. The same precision standard applies.
Three Formulations, Three Targets
Evōke's three herbal formulations extend the full spectrum psilocybin base toward specific neurological targets. Each herbal adjunct is selected for a documented mechanism relevant to the formulation goal, not for general wellness claims.
Specific ingredient formulations and precise mechanisms are documented in the member resource library. What is public is the selection framework: mechanism first, ingredient second. No ingredient is included without a documented mechanistic rationale relevant to the formulation target. This is what distinguishes a precision formulation from a wellness blend.
Evidence Landscape
Well established
First-pass hepatic metabolism of psilocybin · Cannabis entourage effect as conceptual precedent · Honey matrix properties (pH, hygroscopicity, antimicrobial) · Baeocystin and norbaeocystin identified in psilocybin mushroom alkaloid profile
Emerging
Alkaloid interaction profiles in multi-constituent psilocybin preparations · Bioavailability variation across delivery formats · Dose consistency outcomes in different preparation approaches
Not yet studied
Direct comparison of full spectrum vs isolated psilocybin pharmacokinetics · Honey matrix effect on psilocybin absorption · Beta-glucan interaction with psilocybin alkaloid uptake
References
- Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 163(7):1344-1364.
- Hasler F, et al. (2004). Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma. Pharmaceutical Research. 19:383-385.
- Sherwood AM, et al. (2020). Synthesis and biological evaluation of tryptamines found in hallucinogenic mushrooms. Journal of Natural Products. 83(2):461-467.
- Crews C. (2009). Aspects of the chemistry of honey and its authenticity testing. Food Chemistry.
- Mori K, et al. (2009). Improving effects of Yamabushitake on mild cognitive impairment. Phytotherapy Research. 23(3):367-372.
- Jacobs BL, et al. (2000). Adult brain neurogenesis and psychiatry. Nature Reviews Neuroscience. 1:11-17.
- Stamets P. (2019). Psilocybin Mushrooms of the World. Ten Speed Press.
Formulation details are for members.
Specific ingredient rationale, dose ranges, and preparation guidance live in the member resource library.
Request Membership